Oxygen Biotherapeutics Announces It Will Present at OneMedForum Conference on Wednesday January 9th

  Oxygen Biotherapeutics Announces It Will Present at OneMedForum Conference
  on Wednesday January 9th

Webcast will be made available on the company’s web site oxybiomed.com

Business Wire

MORRISVILLE, N.C. -- January 8, 2013

Oxygen Biotherapeutics, Inc. ("Oxygen") (NASDAQ: OXBT) announced today the
Company will be presenting at the 6^th Annual OneMedForum Emerging Company
Finance Conference to be held at the Sir Francis Drake Hotel in San Francisco
this week. Michael Jebsen, President and Chief Financial officer, will present
a corporate overview and update on Wednesday, January 9^th at 9:40 am PST. A
link to access the webcast of this presentation is available on the Investors
tab of Oxygen’s website www.oxybiomed.com.

The OneMedForum San Francisco conference, runs concurrently with the J.P.
Morgan Annual Healthcare Conference. These conferences are widely attended by
investors and corporate executives interested in partnering, licensing,
collaborating or investing. Attendees typically include institutional
investors, buy and sell-side analysts, high net worth individual investors,
senior healthcare and life science executives looking for investment
opportunities. The conference offers market insights, licensing opportunities,
acquisitions, joint ventures and strategic partnership networking

Additional information can be found via: www.onemedplace.com.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative
pharmaceuticals and medical devices in the field of oxygen therapeutics and
Defense Medicine(TM). The company has developed a perfluorocarbon (PFC)
therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and
has out-licensed an implantable glucose sensor. These products are based upon
core technologies that include biomedical applications for PFCs as well as
medical and industrial applications for biosensors. Each of the product
candidates is designed with advantages over currently marketed products in
major markets including traumatic brain injury, sickle cell crisis, trauma,
wound care, decompression sickness, acute respiratory distress syndrome,
stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and
cosmetic applications which are being marketed under the Dermacyte name. More
information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company's judgment as of
the date of this release. These statements include the expansion of
development of Oxycyte and the timing of the introduction of this new product.
The forward-looking statements are subject to a number of risks and
uncertainties including matters beyond the company's control that could lead
to delays in new product introductions and customer acceptance of these new
products, and other risks and uncertainties as described in our filings with
the Securities and Exchange Commission, including in the current Form 10-Q
filed on December 14, 2012, and our annual report on Form 10-K filed on July
24, 2012, as well as other filings with the SEC. The company disclaims any
intent or obligation to update these forward-looking statements beyond the
date of this release. This caution is made under the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995.


Oxygen Biotherapeutics, Inc.
Ellen Corliss, 919-855-2112
Senior Vice President,
Corporate Communications & Investor Relations
Press spacebar to pause and continue. Press esc to stop.